Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) summarizes one of his main highlights from the 27th Congress of the European Hematology Association (EHA). The phase III QuANTUM-First trial (NCT02668653) assessed quizartinib in relapsed/refractory FLT3–internal tandem duplication positive acute myeloid leukemia. The primary endpoint of the study was overall survival and this showed that treatment with quizartinib reduced the risk of relapse in patients up to 75 years old.
The abstract ‘QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML’ (Abstract S100) was presented at EHA 2022.
Disclosures: Jorge Cortes is consultant for, and has received grant/research support from Novartis, Pfizer, Takeda and Sun Pharma. He is also on the Advisory Board for Novartis and Pfizer.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 27th Congress of the European Hematology Association (EHA).
Share this Video
Related Videos In Leukaemia
Robin Foà, EHA 2023: José Carreras Award presentation – research on Philadelphia-positive acute lymphoblastic leukaemia
Each year, the EHA Board presents the José Carreras Award to honour leaders in haematological research. touchONCOLOGY caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss his receipt of the José Carreras Award and the key take-home messages of his award presentation, which focused on Philadelphia-positive acute lymphoblastic leukaemia research. The presentation […]
Robin Foà, EHA 2023: New developments in the treatment of Philadelphia-positive acute lymphoblastic leukaemia
The management of patients with Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL) has evolved over the last few decades, with new and exciting treatments becoming increasingly available. We caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss the history of Ph+ ALL research and top trials in the treatment of Ph+ ALL. The […]
Arnon Kater, EHA 2023: MURANO substudy analysis: Venetoclax-rituximab in patients with chronic lymphocytic leukaemia
The phase III MURANO trial (NCT02005471) reported that venetoclax plus rituximab (venR) resulted in higher progression-free survival and overall survival than bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukaemia. The unmet needs in the treatment of chronic lymphocytic leukaemia, as well as the aims, main findings and clinical significance of the final MURANO […]